| Name | Title | Contact Details |
|---|
Tremont Strategies Group is a full service government affairs consulting firm offering a wide range of practices and committed to offering the highest quality service to its clients. Our firm specializes in executing complex, multi-faceted campaigns by utilizing a comprehensive approach to engage stakeholders, policymakers and the general public in order to educate and advocate for our client`s position. With decades of experience in the public and private sectors, we offer in-depth analysis on policy matters and proposals before state and federal government. Our team provides the expertise and entrepreneurial creativity needed to build successful comprehensive public affairs strategies.
Focus on joint success We are one of the international market and technology leaders for innovative laser marking systems. As a global brand and technology center for laser marking solutions, we are part of the Product Quality and Identification segment of the publicly traded Veralto Corporation. FOBA is a leader in camera-based precision systems, machines and workflows for laser marking and engraving. We help our customers to ensure the traceability of their products, to protect their quality and brands, to design products and to respond to trends and regulations at an early stage – especially in our key markets of medical technology and the automotive, aerospace and electronics industries. With decades of laser application expertise, technology leadership in camera-assisted laser marking and consistent customer and service orientation, we can refer to several thousand successfully installed systems worldwide. https://www.fobalaser.com Imprint: https://www.fobalaser.com/legal-notice/ FOBA Laser Marking + Engraving Brand of ALLTEC Angewandte Laserlicht Technologie GmbH
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Delrin® is a highly adaptable acetal homopolymer resin that bridges the performance gap between plastics and metals and offers unique properties. Manufacturers count on Delrin® for high load mechanical applications and precision parts, where strength, stiffness, stability, and reliability are important. Applications range from gears, safety restraint components, door system, and conveyor systems components to medical delivery devices, ski bindings, zip fasteners and many others across a wide range of products and industries